Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Valeo Pharma Inc. (C:VPH)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for VPH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 02, 2020 07:00 ET
Valeo Pharma Reports its 2020 Second Quarter Results and Initiates $1 Million Debenture Private Placement
Revenues of $2.1 million, up 112% compared to Q2 2019 Net loss of $0.9 million, down 25% compared to Q2 2019 EBITDA loss down 42% at $0.6 million compared to $1.1 million for Q2 2019 MONTREAL, July 2, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today reported its financial results for the second quarter ended April 30, 2020.
Read full article
Jun 08, 2020 07:00 ET
Valeo Pharma Receives Approval from Health Canada for the Transfer of Commercial Rights to Yondelis® in Canada
Yondelis® is an important treatment option for soft tissue sarcoma Commercialization to begin summer 2020 MONTREAL, June 8, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company,  announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis®  to Valeo.  Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
7.55
4.73
8.18
Price to Book - most recent quarter
--
2.28
2.53
Price to Cash Flow per share - TTM
--
8.97
11.10
Price to Free Cash Flow per share - TTM
--
13.31
22.75
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 20205260
May 31, 2020526266
May 15, 2020260195
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Valeo Pharma Inc is a Canada-based specialty pharmaceutical company dedicated to the commercialization of prescription products in Canada. With a focus on neurodegenerative diseases, woman's health, and oncology and supportive care, the Company has a portfolio of products and a platform to manage these products through stages of commercialization.

See business summary

 

Twitter

Search (past week) for $VPH.CA

  • No tweets found